Citigroup Inc Sellas Life Sciences Group, Inc. Transaction History
Citigroup Inc
- $196 Billion
- Q2 2025
A detailed history of Citigroup Inc transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Citigroup Inc holds 42,415 shares of SLS stock, worth $67,439. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,415Holding current value
$67,439% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding SLS
# of Institutions
93Shares Held
23.2MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.84MShares$10.9 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$4.32 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.5 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.37 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$1.79 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $32.7M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...